Oric Pharmaceuticals (NASDAQ: ORIC) awards director 40,000 options

Rhea-AI Filing Summary

Oric Pharmaceuticals director files insider transaction report for new stock options. Director Lori Anne Kunkel reported receiving a stock option covering 40,000 shares of Oric Pharmaceuticals common stock on January 2, 2026. The option has an exercise price of $8.17 per share and is held as a derivative security with direct ownership. According to the vesting terms, 1/12 of the shares subject to the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. The option is scheduled to expire on January 1, 2036, if not exercised earlier.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kunkel Lori Anne

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.17	01/02/2026		A		40,000		(1)	01/01/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

	/s/ Christian Kuhlen, attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ORIC report in this Form 4?

The report shows a grant of a stock option (right to buy) for 40,000 shares of Oric Pharmaceuticals common stock to director Lori Anne Kunkel on January 2, 2026.

What is the exercise price and term of the new Oric (ORIC) stock option?

The stock option has an exercise price of $8.17 per share and is scheduled to expire on January 1, 2036 if not exercised.

How do the 40,000 Oric (ORIC) stock options vest for the director?

According to the disclosure, 1/12 of the shares subject to the option vest on each one-month anniversary of January 2, 2026, leading to full vesting over 12 months.

How many derivative securities does the Oric director hold after this transaction?

After the reported grant, the director beneficially owns 40,000 derivative securities in the form of stock options, held with direct ownership.

What role does the reporting person hold at Oric Pharmaceuticals (ORIC)?

The reporting person, Lori Anne Kunkel, is identified as a director of Oric Pharmaceuticals and is not listed as an officer or 10% owner.

Does this Form 4 involve common stock or derivative securities of ORIC?

The filing reports a transaction in a derivative security, specifically a stock option (right to buy) common stock, rather than a direct trade in common shares.